Article
Oncology
Xiao Huang, Tingting Ma, Yongmei Zhu, Bo Jiao, Shanhe Yu, Kankan Wang, Jian-Qing Mi, Ruibao Ren
Summary: The expression of IRF4 and IRF8 is associated with the MPN phenotype, serving as potential biomarkers for the response to hydroxyurea in ET patients.
FRONTIERS OF MEDICINE
(2022)
Article
Oncology
Srdan Verstovsek, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Ruben A. Mesa
Summary: Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. This article introduces interferon as a potential second-line therapy and mentions an ongoing clinical trial (SURPASS-ET) that will evaluate the efficacy and safety of a new type of interferon (ropeginterferon alfa-2b) compared to anagrelide.
Article
Oncology
Ja Min Byun, Ho Young Kim, Seung-Hyun Nam, Ho-Jin Shin, Seulki Song, Jinny Park, Sang Hoon Han, Yong Park, Young Jin Yuh, Yeung-Chul Mun, Young Rok Do, Sang Kyun Sohn, Sung Hwa Bae, Dong-Yeop Shin, Sung-Soo Yoon
Summary: This study aimed to evaluate the efficacy and safety of first-line anagrelide treatment in high-risk ET patients. The results showed that anagrelide monotherapy was effective in reducing platelet count and achieving platelet normalization, regardless of somatic mutation status. Adverse events such as headache, palpitation, and edema were reported, but the treatment was generally well tolerated.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yingxin Sun, Yifeng Cai, Jiannong Cen, Mingqing Zhu, Jinlan Pan, Qian Wang, Depei Wu, Suning Chen
Summary: Peg-IFN demonstrates promising hematologic and molecular responses in patients with PV and ET, and is safe, effective, and well tolerated in most patients. However, a small percentage of patients had to discontinue treatment due to drug-related toxicity. Further exploration of Peg-IFN alone or in combination with other drugs is needed to minimize treatment-related toxicity and improve tolerability.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Jason Gotlib
Summary: Polycythemia vera is a myeloproliferative neoplasm driven by mutations, and treatment selection should consider various variables. Obtaining high-level evidence is challenging due to low event rates and longer-term endpoints.
Article
Hematology
Kittitat Chiaranairungrot, Komkrich Kaewpreechawat, Chanwit Sajai, Narueporn Pagowong, Nissa Sukarat, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Adisak Tantiworawit, Lalita Norasetthada, Ekarat Rattarittamrong
Summary: This study investigated the prevalence, clinical outcomes, and factors associated with hydroxyurea resistance or intolerance among patients with polycythemia vera and essential thrombocythemia. The study found that patients who had hydroxyurea resistance or intolerance had a significantly increased risk of bleeding events. Low baseline hemoglobin levels, age over 60, and splenomegaly were identified as risk factors for hydroxyurea resistance or intolerance.
Article
Nursing
Ruth Madden Foreman, Richard Brzustowicz
Summary: This article introduces Essential thrombocythemia, a myeloproliferative neoplasm (MPN) characterized by excessive clonal platelet production and poorly formed platelets. Medical management aims to reduce symptoms and exacerbations of thrombosis and hemorrhage. Primary care providers play a crucial role in increasing awareness, diagnosing, and co-managing this complex disease.
JNP- THE JOURNAL FOR NURSE PRACTITIONERS
(2023)
Article
Hematology
Yoko Edahiro, Hajime Yasuda, Akihiko Gotoh, Soji Morishita, Toshifumi Suzuki, Jun Takeda, Jun Ando, Miyuki Tsutsui, Atsuo Itakura, Norio Komatsu
Summary: ET patients with high-risk pregnancies may benefit from interferon (IFN) therapy to reduce complications. Close monitoring and early intervention throughout pregnancy can help to manage risks effectively.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2021)
Article
Primary Health Care
Steven Fox, Leslie Griffin, Dominique Robinson Harris
Summary: Polycythemia vera is a myeloid malignancy characterized by elevated red blood cell count, often accompanied by increased platelets and white blood cells. Treatment options include low dose aspirin and phlebotomy to reduce thrombotic events and improve quality of life.
AMERICAN FAMILY PHYSICIAN
(2021)
Review
Medicine, General & Internal
Masafumi Sugawara, Sho Okada, Masato Kanda, Tohru Iseki, Emiko Sakaida, Yoshio Kobayashi
Summary: Anagrelide, a medication used to treat essential thrombocythemia, can cause cardiomyopathy and heart failure. A Japanese patient with ET developed heart failure after 18 months of treatment with anagrelide, but the cardiac function returned to normal after discontinuation of the medication and guideline-directed heart failure therapy.
Article
Oncology
Lukas Schrickel, Florian H. Heidel, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Andreas Hochhaus, Martin Griesshammer, Kai Wille
Summary: This study analyzed data from 23 women with high-risk ET pregnancies, finding that the use of IFN significantly increased the live birth rate to 73.5% with no fatal maternal events and manageable side effects.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Giulia Benevolo, Elena M. Elli, Francesco Cavazzini, Gianni Binotto, Alessia Tieghi, Mario Tiribelli, Florian H. Heidel, Massimiliano Bonifacio, Novella Pugliese, Giovanni Caocci, Monica Crugnola, Francesco Mendicino, Alessandra D'Addio, Simona Tomassetti, Bruno Martino, Nicola Polverelli, Sara Ceglie, Camilla Mazzoni, Rikard Mullai, Alessia Ripamonti, Bruno Garibaldi, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Giuseppe A. Palumbo, Alessandro Andriani, Michele Cavo, Roberto Latagliata, Valerio De Stefano
Summary: The prognostic relevance of complete response to hydroxyurea, predictors of response, and patients' triggers for switching to ruxolitinib in polycythemia vera are uncertain. Many PV patients receive underdosed hydroxyurea, leading to lower response and toxicity rates. Splenomegaly and other symptoms are the main drivers for early switch to ruxolitinib despite poor response to hydroxyurea.
Article
Hematology
Marc J. B. Dam, Rasmus K. Pedersen, Trine A. Knudsen, Morten Andersen, Vibe Skov, Lasse Kjaer, Hans C. Hasselbalch, Johnny T. Ottesen
Summary: The study suggests that for patients with myeloproliferative neoplasms (MPNs), treatment with Hydroxyurea does not lead to a sustained decrease in the JAK2V617F allele burden or sustained normalization of elevated cell counts.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Young Hoon Park, Sewon Lee, Yeung-Chul Mun, Dong Jin Park
Summary: This study compared the impact of ELN and mELN criteria on the development of HU resistance or intolerance in high-risk ET patients receiving HU treatment. The mELN criteria were found to more accurately identify HU resistance and intolerance and had an independent prognostic impact on transformation-free survival. The mELN criteria can be used to identify high-risk ET patients who may benefit from second-line therapy.
Review
Hematology
Hannah Goulart, John Mascarenhas, Douglas Tremblay
Summary: This review discusses the complications and risk stratification methods in patients with myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thrombocythemia (ET). Current treatment options for low-risk patients are limited, but novel therapies are being investigated.
ANNALS OF HEMATOLOGY
(2022)